Author of

• 10743

  +

  P1.10 - Poster Session 1 - Chemotherapy (ID 204)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10794

    +

    P1.10-051 - Pemetrexed maintenance treatment in advanced non squamous Non-Small Cell Lung Cancer (NSCLC) (ID 3055)

    09:30 - 09:30  |  Author(s): A. Zemmour
    • Abstract

    Background
    Patients with advanced non squamous NSCLC benefit from pemetrexed maintenance therapy after induction therapy with a platinum-containing, pemetrexed or non-pemetrexed doublet. We evaluated the efficacy and safety of pemetrexed maintenance therapy in advanced non squamous NSCLC.

    Methods
    We used pemetrexed (500 mg/m2 every 21 days) and best supportive care in patients with advanced, non squamous NSCLC who had not progressed after at least 4 cycles of induction chemotherapy. Pemetrexed was administered with folic acid and vitamin B12 supplementation until disease progression or the development of intolerable toxicity.

    Results
    Eleven patients were enrolled. Patient characteristics were: 9 men, 2 women, median age 60 years (range 44 to 73), 2/4/5 never, former and current smokers, 9 adenocarcinoma, 2 large cell, 3 stage IVa, 8 stage IVb, 100% ECOG PS 1. A total of 87 cyclesof pemetrexed was administered [median 6 (range 2 to 23)], relative dose intensity 91%. Nine pts were evaluable for tumor response 1 PR, 7 SD, 1 PD. Median PFS was 4.14 months (95% CI 3.3 to 9.5 mo). Toxicity was anemia G 1/2 (3/4 pts), neutropenia G 2 (1 pt), fatigue G 1/2 (8/3 pts),nausea-vomiting G 1/2 (5/2 pts), mucositis G 1/2 (2/2 pts), oedema (0 pt).

    Conclusion
    Pemetrexed maintenace therapy is a well tolerated and an effective option for patients with advanced non-squamous NSCLC. The study is ongoing.